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Hamilton DL, Philp A, MacKenzie MG, Patton A, Towler MC,
Gallagher IJ, Bodine SC, Baar K. Molecular brakes regulating
mTORC1 activation in skeletal muscle following synergist ablation.
Am J Physiol Endocrinol Metab 307: E365–E373, 2014. First pub-
lished June 24, 2014; doi:10.1152/ajpendo.00674.2013.—The goal of
the current work was to profile positive (mTORC1 activation, auto-
crine/paracrine growth factors) and negative [AMPK, unfolded pro-
tein response (UPR)] pathways that might regulate overload-induced
mTORC1 (mTOR complex 1) activation with the hypothesis that a
number of negative regulators of mTORC1 will be engaged during a
supraphysiological model of hypertrophy. To achieve this, mTORC1-
IRS-1/2 signaling, BiP/CHOP/IRE1, and AMPK activation were
determined in rat plantaris muscle following synergist ablation (SA).
SA resulted in significant increases in muscle mass of 4% per day
throughout the 21 days of the experiment. The expression of the
insulin-like growth factors (IGF) were high throughout the 21st day of
overload. However, IGF signaling was limited, since IRS-1 and -2
were undetectable in the overloaded muscle from day 3 to day 9. The
decreases in IRS-1/2 protein were paralleled by increases in GRB10
Ser501/503 and S6K1 Thr389 phosphorylation, two mTORC1 targets
that can destabilize IRS proteins. PKB Ser473 phosphorylation was
higher from 3–6 days, and this was associated with increased TSC2
Thr939 phosphorylation. The phosphorylation of TSC2 Thr1345 (an
AMPK site) was also elevated, whereas phosphorylation at the other
PKB site, Thr1462, was unchanged at 6 days. In agreement with the
phosphorylation of Thr1345, SA led to activation of AMPK1 during
the initial growth phase, lasting the first 9 days before returning to
baseline by day 12. The UPR markers CHOP and BiP were elevated
over the first 12 days following ablation, whereas IRE1 levels
decreased. These data suggest that during supraphysiological muscle
loading at least three potential molecular brakes engage to downregu-
late mTORC1.
mTORC1; S6K1; AMPK; hypertrophy; skeletal muscle
SKELETAL MUSCLE MASS IS DETERMINED by net protein balance
within the muscle. During periods of growth, the rate of protein
synthesis is greater than degradation (34). Load-induced in-
creases in anabolic signals result in an increase in protein
synthesis and therefore a shift toward positive protein balance.
Of these anabolic signals, the activation of complex 1 of the
mechanistic (mammalian) target of rapamycin (mTORC1) is a
fundamental requirement (8, 12). The activity of mTORC1 is
known to be regulated positively by anabolic effectors such as
growth factors, amino acids, and loading and negatively by
catabolic signals such as metabolic stress (14). Therefore,
understanding positive and negative regulators of mTORC1
activation during a growth stimulus is essential to understand-
ing load-induced skeletal muscle hypertrophy.
The best-studied mechanisms for activating mTORC1 and
protein synthesis are via receptor tyrosine kinase activation by
growth factors such as insulin-like growth factor (IGF)-I and
insulin (36) and nutritional activation by branched-chain amino
acids (36). Growth factors, like IGF-I, play a significant role in
skeletal muscle developmental growth (9). IGF-I and MGF
(mechano growth factor, the IGF-IEc splice variant) are also
induced in skeletal muscle in a load-dependent manner (6, 29)
and muscle-specific overexpression of IGF-I can induce sig-
nificant hypertrophy (3). These data suggest that autocrine
production of growth factors plays an important role in load-
induced muscle growth. This hypothesis has been challenged
in situ (7, 20, 21, 32), in genetic models following overload
(39), following acute resistance type contractions (15, 41), and
in wild-type mice following overload (30). Furthermore, recent
data suggest that MGF has little role in regulating the signals
that control skeletal muscle hypertrophy (10). Therefore,
whether insulin or IGFs plays a significant role during in vivo
load-induced hypertrophy is still equivocal.
Two other potential ways to regulate mTORC1 activity and
possibly load-induced muscle hypertrophy have been de-
scribed. First, the 1-catalytic subunit of AMP-activated pro-
tein kinase (AMPK) is activated by chronic overload (28).
Since AMPK is known to decrease mTORC1 activity in vitro
through the phosphorylation of tuberous sclerosis complex 2
(TSC2) at Thr1345 (24) or raptor at Ser792 (13), it is not
surprising that knocking out AMPK1 results in greater over-
load-induced hypertrophy (31). However, whether endogenous
AMPK limits mTORC1 in vivo has yet to be determined.
Second, endoplasmic reticulum (ER) stress through the regu-
lation of PKB and PRAS40 could limit the activation of
mTORC1 in muscle (4). However, whether ER stress is acti-
vated during overload hypertrophy and limits growth in vivo
has yet to be determined.
The aim of the current study was to establish a detailed time
course profile of anabolic signals (insulin/IGF-I signaling
through IRS-1/2), and potential catabolic signals (ER stress
and metabolic stress/AMPK activation) during overload-in-
duced skeletal muscle hypertrophy and determine whether
alterations in any of these factors are associated with altered
mTORC1 activity during supraphysiological hypertrophy in-
duced by synergist ablation. We hypothesized that a number of
molecular brakes will be engaged to restrain mTORC1 activity.
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MATERIALS AND METHODS
Ethical approval. All procedures on Female Wistar rats (200 g,
from Charles River Laboratories, Tranent, UK) were approved by the
University of Dundee Research Ethics Committee and performed
under UK Home Office project licence no. 60/3441. All surgical and
collection procedures took place under inhaled anesthetic using a
2.5% concentration of isoflurane throughout. Animals were first
sedated in an anesthetic induction box before placing the animal into
the surgical field. Animals were allowed to recover for the appropriate
time period post-stimulation and were terminated after muscle collec-
tion under anesthesia.
Synergist ablation. Twenty rats were used for this study, and they
were randomly assigned to five treatment groups, 3 days (n  4), 6
days (n  4), 9 days (n  4), 12 days (n  4), and 21 days (n  4)
of muscle hypertrophy induced by unilateral ablation of the gastroc-
nemius (GTN) and soleus (SOL) muscles. Animals were anesthetized,
and the area above the incision was shaved and sterilized. The
GTN and SOL muscles were isolated and severed at the Achilles tendon,
and the distal two-thirds of the GTN and the whole SOL were
removed, leaving the plantaris (PLN) intact. The overlying skin and
fascia were sutured separately, and the animal was then moved to a
temperature-controlled environment to recover. All animals returned
to normal activity within 1 h. In the recovery period prior to collec-
tion, animals were monitored on a daily basis for signs of pain or
postoperative infection. However, none of the animals showed any
sign of undue discomfort or distress. On the day of collection, animals
were anesthetized, and hypertrophied and contralateral control mus-
cles were rapidly removed, snap-frozen in liquid nitrogen, and stored
at80°C until processing. Following muscle collection, animals were
terminated by cervical dislocation.
Tissue extraction and processing. Muscles were rapidly removed,
rinsed of blood, snap-frozen in liquid nitrogen, and stored at 80°C.
For processing, muscle was powdered on dry ice using a mortar and
pestle and polytron homogenized in 10-fold mass excess of ice-cold
sucrose lysis buffer [50 mM Tris, pH 7.5, 250 mM sucrose, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 50 mM NaF, 1 mM
NaVO4-Na2(PO4)2, and 0.1% DTT]. The homogenate was briefly
vortexed and centrifuged at 4°C for 10 mins at 10,000 g to remove
insoluble material. Protein concentrations were determined using the
DC protein assay (Bio-Rad, Hercules, CA).
Western blotting. Equal aliquots of protein were diluted in Laemmli
sample buffer and boiled for 5 min, and then 5–10 g of sample was
subjected to SDS-PAGE on 10% acrylamide gels at a constant current
equal to 20 mA per gel and transferred to Protran nitrocellulose
membrane (Whatman, Dassel, Germany) using a Bio-Rad semidry
transfer apparatus at 100 V for 1 h. Membranes were blocked in 5%
dry milk in TBST (Tris-buffered saline  0.1% Tween) and then
incubated overnight at 4°C with appropriate primary antibody in
TBST at 1:1,000. The following day, membranes were washed three
times in TBST before incubation for 1 h at room temperature with
peroxidase-conjugated secondary antibodies in TBST at 1:10,000
(Perbio Science, Cramlington, UK). Antibody binding was detected
using an enhanced chemiluminescence HRP substrate detection kit
(Millipore, Watford, UK). Imaging and band quantification were
carried out using a Chemi Genius Bioimaging Gel Doc System
(Syngene, Cambridge, UK). Given the rapid rate of protein accretion
in the ablated muscle, appropriate loading controls proved to be an
issue for the overloaded samples. Our usual loading control, eEF2
(eukaryotic elongation factor 2), changed with overload. Actin also
changed substantially (data not shown). Therefore, to assess equal
loading per gel, total protein content was determined via Ponceau
staining or GAPDH.
Antibodies. Sheep anti-IRS-2 antibody was obtained from the
Division of Signal Transduction Therapy (DSTT. University of
Dundee), rabbit anti-IRS-1, anti-GRB10, and anti-pGRB10 Ser501/503
were from Millipore (Billerica, MA), rabbit anti-S6K1 and rabbit
anti-TSC2 were from Santa Cruz Biotechnology (Santa Cruz, CA),
sheep anti-AMPK1, anti-AMPK2, and anti-phospho-(p-)TSC2
Ser1345 antibodies were a kind gift from Prof. Grahame Hardie
(University of Dundee), rabbit-anti-p-S6K1 Thr389, total (t-)eEF2,
p-TSC2 Thr1642, and p-TSC2 Thr939, PKB, p-PKB Thr308, PKB
Ser473, p-PRAS40, t-PRAS40, and an ER stress signaling sample kit
were from Cell Signaling Technologies. All other chemicals were
from Sigma-Aldrich, unless stated otherwise.
AMPK1 activity assay. Approximately 50 mg of PLN powder was
suspended in 100 l of homogenization buffer [50 mM Tris·HCl, 0.25
M mannitol, 50 mM NaF, 5 mM sodium pyrophosphate, 150 mM
NaCl, 5 g/ml soybean trypsin inhibitor, 1 mM DTT, 0.1 mM PMSF,
1% (vol/vol) Triton X-100] per 20 mg of tissue and further homog-
enized using a hand-held polytron. The samples were left to rotate at
4°C for 30 min, and then cell debris was pelleted by centrifugation at
17,600 g for 5 min. The supernatants were removed and protein
concentrations determined. Sheep anti-AMPK1 antibody (5 g) was
used to immunoprecipitate AMPK from 200 g of muscle lysate for
2 h at 4°C. The immunoprecipitates were washed in homogenization
buffer and then resuspended in assay buffer [50 mM HEPES, 1 mM
DTT, 0.02% (vol/vol) Brij-35]. AMP, [-32P]ATP (200 cpm/pmol),
and the peptide substrate AMARAASAAALARRR were added to the
immunoprecipitate at a final concentration of 200 m. The assays
were carried out for 15 min at 30°C and terminated by applying 30 l
of the reaction mixture to P81 papers (Whatman, Maidstone, UK).
ATP incorporation into the peptide substrate was inhibited by placing
the filter paper in 1% orthophosphoric acid. Phosphate incorporation
into the peptide was measured as previously described (17).
Immunoprecipitations. Rabbit TSC2 antibody (2 g) was incu-
bated with 1 mg of PLN lysate overnight at 4°C. The following day,
TSC2 was immobilized on protein G-Sepharose for 1 h. Immunocom-
plexes were washed two times in sucrose lysis buffer and two times in
TNE (10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1 mM
Na2VO4). The immunocomplexes were resuspended in 30–50 lof
1	 Laemmli sample buffer (LSB). The samples were boiled and spun
briefly to pellet the beads, and 15 l was loaded per well for
SDS-PAGE separation, and transferred as described above.
mRNA extraction. Total RNA was extracted from 100 mg of
powdered muscle using TRIzol following the manufacturer’s instruc-
tions. RNA was quantified using an Ultraspec 2100 Pro spectropho-
tometer (Amersham Biosciences; Amersham, UK). Total RNA was
then subjected to electrophoresis to check mRNA quantity and qual-
ity.
Reverse transcription and qPCR. Total RNA (1 g) was used to
synthesize first-strand cDNA with AMV reverse transcriptase and
oligo(DT) primers (Promega, Madison, WI) using the manufacturer’s
recommendations. cDNA was diluted 1:15 before use in qPCR. qPCR
was performed using an Eppendorf mastercycler ep real-time thermo-
cycler (Hamburg, Germany) along with a SYBR Green jump start
taq-ready mix and 96-well plates (Fisher). PCR reactions were per-
formed according to the manufacturer’s instructions with the follow-
ing primers: IGF-I (fwd TACTTCAACAAGCCCACAGG, rev CT-
CATCCACAATGCCTGTCT), IGF-II (fwd GTCGATGTTGGT-
GCTTCTCATC, rev GCTTGAAGGCCTGCTGAAGTAG), MGF
(fwd TACTTCAACAAGCCCACAGG, rev CCTTTCCTTCTCCT-
TTGCAG), IRS-1 (fwd GCATCAACTTCCAGAAGCAA, rev
GGAGGATTGCTGAGGTCATT), and GAPDH (fwd TGGAAA-
GCTGTGGCGTGAT, rev TGCTTCACCACCTTCTTGAT) used at a
concentration of 10 pM. PCR conditions were as follows: initial
denaturation at 95°C for 15 min followed by 40 cycles of denaturation
at 94°C for 15 s, annealing at 56°C for 30 s, and extension at 72°C for
30 s. A melt curve was then performed to assess the specificity of the
primers and the presence of primer dimers. PCR efficiencies were
determined for each primer set. The ratio of expression of the gene of
interest normalized against the standard was computed according to
the equation proposed by Pfaffl et al. (33).
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Statistics. Data are given as means
 SE; n 3 or 4 per group. For
the analysis of Western blot data where different sets of animals were
used across a time course but samples were paired within a time point,
the data were modeled using linear mixed effects with treatment, time,
or the interaction between treatment and time as a fixed effect and
animal as a random effect. We used the approach of Kenward and
Roger (26) to generate P values for these models, which is suitable for
small samples. If a statistically significant main effect was found,
between-level differences were assessed using Tukey contrasts. These
analyses were carried out using the R statistical programming lan-
guage (37) and the lme4, pbkrtest, and multcomp packages. Statistical
significance was set at P  0.05. The mRNA data were normalized
independently for each time point. These data were analyzed using
paired t-tests within the time point and P values corrected using
Hochberg’s step-up procedure (18).
RESULTS
PLN muscle growth following synergist ablation. Following
ablation of the SOL and GTN, the PLN muscle underwent a
rapid and sustained increase in wet mass at a rate of 4%/day
(Fig. 1). At 3 days, the wet mass of the ablated PLN was
20.3 
 3.8% greater than the contralateral control. Steady
growth was observed until the final collection point at 21 days,
by which time the wet mass of the ablated PLN was 81.2 

12.4% greater than the contralateral control. Animal body
weights were also recorded to ensure animals continued to gain
weight. The animals continued to increase body weight
throughout the study; therefore, the degree of muscle growth
was expressed as PLN mass/body mass (Fig. 1).
Growth factor signaling following synergist ablation. It
has previously been hypothesized that overload hypertrophy
is induced partly by the activation of canonical growth
factor pathways (6). We therefore first measured the expres-
sion of a number of key growth factors that are known to be
mechanically sensitive: IGF-I, MGF, and IGF-II. The ex-
pression of all three growth factors increased significantly at
day 12 of the overload period, while IGF-II was also
significantly elevated at day 6 (Fig. 2A). Next, we sought to
estimate the activation of receptor tyrosine kinases by de-
termining the association of PI3K with IRS-1/2, a crucial
step in the canonical growth factor signaling cascade. At 3
days post-ablation, we could not detect PI3K association
with either IRS-1 or IRS-2. We therefore instead determined
the levels of IRS-1/2 following synergist ablation (Fig. 2B).
Remarkably, both IRS-1 and -2 levels were below detection
at both 3 and 6 days following synergist ablation. By day 9,
IRS-1 and -2 protein began to return but remained well
below control levels at 21 days. To better understand the
control of IRS-1 expression, we assessed the impact of
synergist ablation on IRS-1 mRNA levels (Fig. 2C). Sur-
prisingly, IRS-1 mRNA levels were significantly elevated at
all time points post-surgery (Fig. 2C). These data indicate
either that the IRS-1 mRNA transcripts are entering a
translationally inactive pool or that the degradation of IRS-1
protein far exceeds the translation of new IRS-1 from the
increased transcript number.
S6K1 and GRB10 phosphorylation. mTORC1 has been pro-
posed to negatively regulate IRS-1/2 content via two mecha-
nisms; first via S6K1 and second via GRB10. We therefore
measured S6K1 Thr389 and GRB10 Ser501/503 phosphorylation
Fig. 1. Overload-induced hypertrophy. Profile of rat plantaris (PLN) wet
weight normalized to body weight following synergist ablation (ABL) of
gastrocnemius and soleus muscles for 3, 6, 9, 12, or 21 days. *Significantly
different from contralateral control (CON) (P  0.05).
Fig. 2. Growth factor and IRS-1/2 expression. A: time course of changes in
IGF-1Ea/Ec and IGF-2 mRNA expression. B: representative blots showing
IRS-1/2 protein expression with GAPDH as a loading control. C: time course
of changes in mRNA expression of IRS-1. *Significantly different from
contralateral control.
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over the same time period (Fig. 3B). S6K1 phosphorylation at
Thr389 increased significantly up to 12 days and tended to be
higher at 21 days compared with the control (3 days  3.3 

0.9, 6 days  2.3 
 0.3, 9 days  2.2 
 0.4, 12 days  2.2 

0.5-fold; Fig. 3A). This elevation in S6K1 phosphorylation
occurred concomitantly with elevated GRB10 phosphoryla-
tion: GRB10 phosphorylation achieved significance at day 6
(Fig. 3, A and B). Interestingly, the time course of peak
S6K1/GRB10 phosphorylation paralleled IRS-1/2 suppression
and recovery. In addition to the phosphorylation changes there
was a nonsignificant trend for t-S6K1 levels to be elevated at
day 3 and a nonsignificant trend for t-GRB10 to be elevated at
every time point post-ablation.
PKB signaling. To estimate the time course of activation of
PKB, we measured the phosphorylation of PKB at its activa-
tion sites Thr308 and Ser473 (25). In agreement with the work of
Miyaziki et al. (30), we also saw significant increases in the
phosphorylation of PKB 3 days following overload in rats
(Fig. 4A). However, there was no significant change in the
relative phosphorylation of PKB Thr308 or Ser473 due to sig-
nificant changes in the total expression of PKB (Fig. 4A). We
did observe increases in the phosphorylation of TSC2 at the
PKB-dependent Ser939 phosphorylation site (23) (Fig. 4B),
indicating that, although IRS-1/2 levels were undetectable,
PKB was still capable of being activated by mechanical load-
ing. In addition, levels of PKB protein were mechanically
sensitive, increasing significantly at days 6 and 21. However,
another target of PKB, PRAS40, did not undergo any signifi-
cant changes either in phosphorylation status or in total ex-
pression.
AMPK1 activity following synergist ablation. To determine
the time course of activation and how AMPK could decrease
mTORC1 activity over a hypertrophy time course, we assayed
AMPK1 activity at 3, 6, 9, 12, and 21 days and TSC2
phosphorylation via immunoprecipitation at Ser1345 and
Thr1462. AMPK1 activity was significantly elevated at 3, 6,
and 9 days (3 days  2.26 
 0.19-fold; 6 days  3.22 

0.18-fold; and 9 days  2.66 
 0.28-fold) but returned to
baseline by day 12 (Fig. 5). The phosphorylation of TSC2 was
determined at day 6 when AMPK1 activity and PKB phos-
phorylation peaked. The phosphorylations of Ser1345 and
Thr1462 were determined since these residues are phosphory-
lated by AMPK and PKB, respectively (23). Consistent with
previous work from our laboratory (28), the phosphorylation of
TSC2 at Ser1345 was significantly elevated following ablation
(Fig. 5A). However, we were unable to detect any significant
change in the phosphorylation of TSC2 at Thr1462 (Fig. 5B).
These data suggest that TSC1/2 may be in a more active mode
following ablation and may explain the inhibitory effect of
AMPK1. Interestingly, we also saw a significant increase in
the total amount of TSC2 protein (Fig. 5C) at this time point,
indicating that increased expression of TSC2 may act as an
additional brake on mTORC1 signaling in addition to the
control of TSC2 phosphorylation.
UPR following synergist ablation. ER stress can inhibit
mTORC1 activation in muscle following high-fat feeding in
mice (5), and inducers of ER stress lead to anabolic resistance
in C2C12 myotubes by impairing mTORC1 activation (4). To
estimate ER stress, we measured the protein chaperone BiP (B
cell immunoglobulin-binding protein), the proapoptotic protein
CHOP (C/EB homology protein), and the endoribonuclease
inositol-requiring enzyme-1 (IRE1). The levels of BiP,
CHOP, and IRE1 were therefore measured at 3, 6, 9, 12, and
21 days post-overload. Consistent with the induction of ER
stress during functional overload, the levels of BiP and CHOP
were increased from 3 through 12 days of overload before
returning toward control levels at 21 days (Fig. 6). IRE1
levels, however, were significantly lower, suggesting perhaps a
maladaptive ER stress response (Fig. 6).
Fig. 3. Time course in changes of S6K1 and GRB10 phosphorylation. A:
representative S6K1 Thr389 and total S6K1 phosphorylation and quantification
of S6K1 relative phosphorylation (ratio of phospho-S6K1 to total S6K1). B:
representative blots showing GRB10 Ser501/503 and total GRB10 expression
and quantification of GRB10 relative phosphorylation (ratio of phospho-
GRB10 to total GRB10). *Significantly different from contralateral control
(P  0.05); significantly different from all other data points (P  0.05).
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DISCUSSION
Although it has previously been shown that IGF-I and MGF
are upregulated during overload hypertrophy (6, 29) and that
this correlates with an increase in signaling through mTORC1
(1), a direct relationship between these two events has not been
demonstrated. In fact, Miyazaki et al. (30) have elegantly
shown that PKB phosphorylation trails that of S6K1 and that
the PI3K inhibitor wortmannin does not prevent the early
overload-induced activation of mTORC1. Here, we add data to
Fig. 4. PKB signaling following synergist ablation. A: representative blots for
PKB Thr308, PKB Ser473, and total PKB inset on a graph depicting the fold
change from contralateral control for PKB Thr308, relative PKB Thr308 (ratio
of phospho-PKB to total PKB), PKB Ser473, relative PKB Ser473 (ratio of
phospho-PKB to total PKB), and total PKB expression throughout the time
course post-ablation. B: representative blots for TSC2Ser939 and total TSC2
expression inset on a graph depicting relative phosphorylation (ratio of phos-
pho-TSC2 to total TSC2). C: Representative blots for PRAS40 Ser939 and total
PRAS40 inset on a graph depicting the relative change in PRAS40 Ser939
phosphorylation. *Significantly different from contralateral control (P 0.05).
Fig. 5. AMPK activity and signaling during overload. A: AMPK1 activity
following synergist ablation. B: representative TSC2 phospho- and total blots
following immunoprecipitation (IP) after 6 days of functional overload. C:
quantification of relative TSC2 phosphorylation (ratio phospho-TSC2 normal-
ized to total TSC2 in immunoprecipitate) 6 days following synergist ablation.
*Significantly different from contralateral control (P  0.05).
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support that overload-induced hypertrophy in the rat PLN
occurs in the absence of growth factor signaling. Despite 4%
per day hypertrophy and increased expression of IGF-I, MGF,
and IGF-II in the overloaded PLN, we saw the complete loss of
IRS-1/2 protein. Such a loss of IRS-1/2 protein content would
mean that signaling through the IGF-I receptor to PI3K would
be significantly impaired during functional overload. The loss
of IRS-1/2 protein therefore provides further evidence that
mTORC1 activation during overload occurs independently of
the canonical growth factor signaling pathway. These data
further support the genetic data showing that a functional IGF-I
receptor is not required for the activation of mTORC1 and
hypertrophy following overload (39) and other work that dem-
onstrates that PI3K is not required for loading-induced
mTORC1 activation (15, 30, 41). We interpret the data to mean
that during a prolonged growth stimulus IGF signaling may be
decreased in a negative feedback loop to prevent excess
growth. We have termed this effect a “molecular brake” on
muscle hypertrophy.
The decrease in IRS-1/2 protein within the overloaded mus-
cle could be the result of feedback inhibition downstream of
mTORC1 (16). In culture, high levels of mTORC1/S6K1
activity reduce IRS-1 protein and mRNA levels, diminish its
function (16), and through serine phosphorylation targets it for
proteasomal degradation (43). In vivo, 18 h of extremely high
S6K1 phosphorylation [up to 80-fold (35)] and activity [up to
4-fold (27)] following acute resistance type contractions do not
decrease total IRS-1 or -2 levels immunoprecipated from
muscle lysate (15). However, here we show that a prolonged
and relatively small increase in S6K1 phosphorylation (maxi-
mum of 4-fold) is associated with complete loss of IRS-1/2.
This suggests either that 1) S6K1 activation does not drive the
loss of IRS-1/2 protein; 2) the small increase in S6K1 phos-
phorylation and activity in this context may have a significantly
greater effect on IRS-1/2 protein, possibly due to a difference
in cellular localization; or 3) the longer duration of S6K1
activation is the key factor driving the feedback inhibition.
Interestingly Harrington et al. (16) demonstrate an S6K1-
dependent decrease in IRS-1 mRNA expression. Unexpect-
edly, however, we see significant increases in IRS-1 mRNA
expression in response to SA despite the sustained increase in
S6K1 phosphorylation. We suggest that either the IRS-1
mRNA transcripts enter a translationally inactive pool or that
they are translationally active but IRS-1 degradation rates are
so high that the total protein continues to decrease.
Concurrent with the increase in S6K1 phosphorylation, we
also detected increased phosphorylation of GRB10 at the
mTORC1-dependent Ser501/503 site (22, 42). GRB10 phosphor-
ylation at Ser501/503 has recently been identified in vitro as a
mechanism by which mTORC1 activation inhibits growth
factor signals via destabilizing IRS function (22, 42). Ours are
the first data to show that GRB10 is activated in skeletal
muscle in response to a physiological signal. Furthermore, we
demonstrate that the increase in GRB10 phosphorylation dur-
Fig. 6. Endoplasmic reticulum (ER) stress response to synergist ablation. A: representative blots for ER stress markers following synergist ablation. Time course
of changes in BiP (B), CHOP (C), and IRE1 protein (D) following synergist ablation. GAPDH expression and Ponceau staining were used to demonstrate equal
loading. *Significantly different from contralateral control (P  0.05).
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ing SA is temporal, peaking in the first 3–6 days of growth
before returning to basal levels. Despite S6K1 and GRB10
being mTORC1 substrates, the GRB10/S6K1 time courses are
both very different.
Analogous to a decrease in the capacity for growth factor
signaling, AMPK (24, 40) and ER stress (4) can also attenuate
mTORC1 activation. Therefore, we next sought to determine
the activity of these molecular brakes. As we (28) and others
(31) have previously shown, the activity of AMPK1 increases
following synergist ablation. In rats, AMPK1 activity peaks
at day 6 and returns to control levels by day 12. In mice,
Mounier et al. (31) observed a similar peak in AMPK1
activity at day 7. However, in contrast to rats, AMPK1
activity remained high at day 21. This discrepancy is likely due
to the different metabolic rate of the animals where the higher
activity levels in the mouse results in prolonged AMPK activ-
ity. Mounier et al. also elegantly demonstrated the physiolog-
ical importance of increased AMPK1 activity: an increase in
mTORC1 activity and muscle fiber hypertrophy following
overload in the AMPK1 knockout mouse. In the current
study, we suggest a possible mechanism for the inhibitory
effect of AMPK1 in that the phosphorylation of TSC2 at
Ser1345, the GTPase activating/AMPK site, was increased at
day 6, whereas the phosphorylation of Thr1462, the inactivating/
PKB site, was unchanged despite increased PKB phosphory-
lation and increased phosphorylation at the Thr939 site. The
lack of phosphorylation of TSC2 at Thr1462 is in contrast to
Miyazaki et al. (30), who showed that TSC2 phosphorylation at
Thr1462 was increased at 7 days of overload. The difference
between the two studies could again be a factor of rats vs. mice
but is more likely due to the fact that we immunoprecipitated
TSC2, whereas Miyazaki et al. used a different antibody on
whole muscle lysates. We also find that the total amount of
TSC2 immunoprecipitated from overloaded muscle is signifi-
cantly increased, suggesting an increase in expression of TSC2
as another molecular brake on mTORC1. AMPK also feeds
into mTORC1 activity by phosphorylation of Raptor at Ser792.
We were unable to detect any alteration in Raptor phosphory-
lation Ser792 across the time course, either via standard immu-
noblotting or following Raptor immunoprecipitation (data not
shown). This is consistent with recent work from the Horn-
berger laboratory demonstrating that, although phosphoryla-
tion of Raptor at alternative serine/threonine sites is an impor-
tant process in mechanical activation of mTORC1, the phos-
phorylation status of raptor at the AMPK site Ser792 was
detectable only when Raptor was overexpressed (11). There-
fore, the question still remains as to whether AMPK regulation
of mTORC1 via raptor phosphorylation is a physiologically
relevant event in skeletal muscle.
Beyond the growth inhibitor AMPK and the loss of growth
factor signaling through IRS-1/2, we show for the first time
that overload hypertrophy activates the UPR, suggestive of ER
stress. We have previously demonstrated that ER stress can
block the activation of mTORC1 and limit protein synthesis
(4), suggesting that ER stress is a third molecular brake that
limits rapid growth in skeletal muscle following ablation. ER
stress occurs when unfolded/misfolded proteins accumulate in
the lumen of the ER (38). Normally, the chaperone protein BiP
serves to refold damaged proteins, whereas IRE1 splices and
activates XBP1 (X-box binding protein-1) and degrades
mRNAs within the ER lumen (19). Both of these responses are
positive adaptive changes within the cell. Spliced XBP1 serves
as a transcription factor to increase the protein folding capacity
of the ER (38), and degradation of ER-localized mRNA de-
creases the accumulation of proteins within this organelle and
allows the ER to clear. Together with activating transcription
factor-6 (ATF6) and protein kinase RNA (PKR)-like ER kinase
(PERK), this can return ER equilibrium (38). In overloaded
skeletal muscle, the levels of this integral stress response
protein decreased, suggesting that the adaptive stress response
in skeletal muscle is decreased by functional overload. When
ER stress is prolonged and the adaptive response fails, a
second, maladaptive response is initiated that can lead to
apoptosis (44). Central to the maladaptive response is the
transcription factor CHOP. Consistent with the growth inhib-
itory hypothesis, we found that CHOP levels within overloaded
muscles were elevated from 3 to 21 days, suggesting that the
maladaptive response was preferentially increased in response
to a prolonged growth signal. However, how the maladaptive
UPR could slow growth during functional overload remains to
be determined. Deldicque et al. (4) do, however, shed light on
a potential mechanism. They demonstrate that ER stress induc-
ers inhibit the activation of mTORC1 by inhibiting the input of
PKB on PRAS40. However, we find no significant changes in
the phosphorylation of PRAS40 in response to this hypertrophy
stimulus, suggesting that this negative feedback mechanism is
not engaged in this scenario. Additionally, other energy stress
sensors that can feed into mTORC1 such as REDD1 may also
play a role in the context of overload-induced hypertrophy;
however, we find no significant changes in REDD1 levels in
response to overload hypertrophy (data not shown), suggesting
that this is unlikely to be regulating growth in this context.
Although detailing the regulation of mTORC1 activation as
reported herein is important, it is important to also consider
that these data are generated in a model of supraphysiological
muscle growth. We observed rates of growth of 4%/day.
However, physiological resistance exercise paradigms tend to
induce growth rates of 0.1%/day (2). Therefore, the next
steps would be to transition into human studies to assess
whether these same negative regulators of mTORC1 are en-
gaged during a time course of hypertrophy and whether their
engagement is different in muscles or individuals with different
hypertrophic potential or anabolic resistance.
To conclude, overload-induced hypertrophy results in the
activation of three molecular brakes that may feed back to
attenuate the rate of muscle growth. First, we have demon-
strated that overload-induced stress results in the loss of IRS-
1/2 protein concomitant with increased S6K1 and GRB10
phosphorylation and therefore may limit the capacity for
growth factors to activate mTORC1 after a meal. Second,
metabolic stress results in the activation of AMPK1 and the
phosphorylation of TSC2 at Thr1345 in addition to an increase
in total TSC2, which thereby limits the activation of mTORC1.
Third, high rates of protein synthesis result in ER stress and the
activation of the maladaptive unfolded protein response. The
maladaptive response is epitomized by an increase in CHOP
and a decrease in IRE1, possibly decreasing protein synthesis.
Together, these data suggest that the rate of muscle growth in
vivo is tightly regulated even when faced with a supraphysi-
ological stimulus such as synergist ablation. Furthermore, the
loss of IRS-1/2 from overloaded muscles, likely due to GRB10
activation, supports previously described data showing that
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overload-induced muscle hypertrophy occurs independently of
canonical growth factor signaling (30).
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